HCPCS Level II code J1575 denotes administration of immune globulin combined with hyaluronidase (brand: HyQvia), billed per 100 mg of immune globulin. This code is used for subcutaneous delivery of immunoglobulin therapy facilitated by hyaluronidase to enable larger-volume dosing. Nationally, J1575 is relevant for immunodeficiency and autoimmune disease management where immunoglobulin replacement or immunomodulation is indicated and where subcutaneous administration is preferred or necessary.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise review of coverage and billing context across major commercial and federal payers, including typical sites of service and coding considerations that affect claims processing and site selection.

Readers will learn the clinical context of J1575, expected settings for administration, and the types of benchmarks and policy updates commonly associated with this class of biologic therapy. The summary highlights where to find documentation essentials, common billing modifiers (listed separately), and what to expect in payer policies and prior authorization practices. Data not available in the input is noted where applicable.